Is FDA's Crackdown on Direct-to-Consumer Genetic Testing a Violation of the First Amendment?
New opinion piece in Clinical Chemistry analyzes the information provided to consumers from these tests.
WASHINGTON, May 5, 2014
WASHINGTON, May 5, 2014 /PRNewswire-USNewswire/ -- In November 2013, the U.S. Food and Drug Administration (FDA) ordered the company 23andMe to stop offering its direct-to-consumer DNA testing service, which provided individuals with $99 assessments of their genetic risk for almost 200 disorders. A thought-stimulating opinion piece published in Clinical Chemistry, the journal of AACC, now examines whether this move by FDA is a violation of the First Amendment, or a necessary step to protect consumers.
Read more: http://www.digitaljournal.com/pr/1895833#ixzz31Pomp0CJ